Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 214, Issue 12, Pages 1905-1910Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiw462
Keywords
varicella zoster; vaccine; nursing home; immunogenicity; T cells
Categories
Funding
- Merck Vaccines
Ask authors/readers for more resources
Background. Little is known about the immunogenicity of live-attenuated Oka/Merck varicella zoster virus (VZV)-containing vaccine (hereafter, varicella vaccine) in frail nursing homes residents nor about immune phenotypes associated with a response. Methods. A cohort of 190 frail nursing home residents aged 80-102 years and a cohort of 50 community-dwelling seniors aged 60-75 years (a comparison group) received varicella vaccine. Interferon gamma (IFN-gamma) enzyme-linked immunospot assays were performed before and 6 weeks after vaccination. Cellular markers of immunosenescence were measured in the nursing home elderly. Results. The average number of IFN-gamma spot-forming cells at baseline was significantly lower in the elderly nursing home residents than in the community-dwelling seniors. However, following vaccination, the VZV immune response increased in both cohorts, and no difference was noted in the fold difference of the response between the 2 cohorts. Upon further examination of the elderly nursing home residents, we found that higher frequencies of regulatory T cells and cytomegalovirus-specific CD4(+) T cells correlated negatively with the magnitude of VZV-specific responses. Conclusions. The Oka/Merck varicella vaccine induces VZV immunity in elderly nursing home residents that is similar to that produced in community-dwelling seniors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available